No Data
Noil Immune --- For the fiscal year ending December 2024, the in-house drug development business and the joint pipeline will continue to be promoted.
Noil Immune Biotech <4893> announced its financial results for the fiscal year ending December 2024 on the 14th. Business revenue was 0.007 billion yen (compared to 0.316 billion yen in the previous term), operating loss was 1.069 billion yen (compared to a loss of 0.775 billion yen in the previous term), recurring loss was 0.962 billion yen (compared to a loss of 1.127 billion yen in the previous term), and net loss for the year was 0.964 billion yen (compared to a loss of 1.13 billion yen in the previous term). As for the company's business status for the fiscal year, the self-developed drug discovery business based on PRIME technology and the joint pipeline will continue.
The Nikkei average rose by 24 yen and slightly rebounded, while many stocks on the Main Board fell amid a wait-and-see attitude = afternoon session on the 17th.
On the 17th, the Nikkei average stock price in the afternoon session rose slightly by 24.82 yen to reach 39,174.25 yen, showing a minor rebound. The TOPIX (Tokyo Stock Price Index) increased by 7.69 points to 2,766.90 points. The morning started with a dominant Sell, but transitioned to an upward trend. At 9:17 AM, the Nikkei average hit 39,238.75 yen, up 89.32 yen. Meanwhile, President Trump is considering imposing tariffs on imported Autos around April 2, which is a burden on related stocks.
List of breakout stocks (Part 1) [Ichimoku Kinko Hyo - List of breakout stocks]
○ List of Stocks Above the Clouds Market Code Stock Name Closing Price Leading Span A Leading Span B Main Board <1719> Ando Hazama 1306 1181.25 1158 <1801> Taisei Corporation 6805 6586.25 6743 <1802> Obayashi Corporation 2108 2093 1995.5 <1808> Haseko Corporation 2044 2020 1937.5 <1812> Kajima Corporation 2981 2813.25 2731.5 <183
The Nikkei average rose by 497 yen for a significant three-day consecutive gain, after the Buy orders have subsided, it is somewhat heavy on the upside = afternoon of the 13th.
On the 13th, the Nikkei average stock price rose significantly by 497.77 yen to 39,461.47 yen, continuing to rise for three consecutive days. The TOPIX (Tokyo Stock Price Index) increased by 32.26 points to 2,765.59 points. On the 12th, US Stocks showed mixed results with the Dow Inc falling for the first time in three days while the Nasdaq Composite Index rebounded. However, the Nikkei average started with buying pressure due to the depreciation of the yen. After the initial surge in buying, there were some instances of resistance at higher prices, but as the afternoon session began, it showed a strong upward trend.
The Nikkei Average is up around 445 yen, showing steady movement due to the weak yen and rising U.S. stock Index ETF futures in after-hours trading = 13 days before lunch.
On the 13th at around 10:02 AM, the Nikkei average Stocks was trending approximately 445 yen higher at around 39,410 yen. At 9:49 AM, it reached a high of 39,435 yen and 89 sen, an increase of 472 yen and 19 sen. In the US stock market on the 12th local time, the Dow Inc fell for the first time in three days while the Nasdaq Index ETF rebounded, showing mixed developments as it did on the 11th. Due to the rise in the US January CPI (Consumer Price Index), the depreciation of the yen progressed in the Tokyo market as trading ended yesterday on the 12th.
Selling pressure from the decline of Tokyo Electron and the advancing appreciation of the yen is a burden.
The Nikkei average fell for the first time in four days. It ended trading at 38,787.02 yen, down 279.51 yen (Volume estimated at 2.1 billion 60 million shares). The yen appreciated to the 150 yen level temporarily, weighed down by rising expectations for additional interest rate hikes by the Bank of Japan. Additionally, Tokyo Electron <8035>, which announced good financial results the previous day, fell by about 4%, contributing to the decline. There was also a moment when the Nikkei average dropped to 38,753.20 yen shortly after the opening. On the other hand, buying continued for stocks with good financial results, etc.
